Semper Augustus Investments Group LLC Sells 72 Shares of Sanofi (SNY)
Semper Augustus Investments Group LLC cut its holdings in shares of Sanofi (NYSE:SNY) by 0.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,188 shares of the company’s stock after selling 72 shares during the quarter. Sanofi makes up approximately 3.9% of Semper Augustus Investments Group LLC’s portfolio, making the stock its 5th largest holding. Semper Augustus Investments Group LLC’s holdings in Sanofi were worth $5,040,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SNY. Harbour Capital Advisors LLC purchased a new stake in Sanofi during the first quarter valued at about $113,000. Parallel Advisors LLC lifted its holdings in Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares during the last quarter. Eagle Ridge Investment Management purchased a new stake in Sanofi during the second quarter valued at about $160,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in Sanofi by 6,188.3% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after purchasing an additional 3,713 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. lifted its holdings in Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares during the last quarter. 9.33% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have commented on SNY. BidaskClub raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Friday, June 2nd. HSBC Holdings plc raised shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and set a $55.00 price objective on shares of Sanofi in a report on Friday, September 1st. Finally, J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a report on Friday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $54.00.
In related news, major shareholder Sanofi acquired 105,820 shares of the stock in a transaction dated Thursday, August 24th. The shares were purchased at an average cost of $482.04 per share, with a total value of $51,009,472.80. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.00% of the stock is owned by insiders.
Shares of Sanofi (NYSE:SNY) traded down 0.60% during midday trading on Friday, hitting $48.43. The stock had a trading volume of 2,378,561 shares. The firm has a market cap of $121.63 billion, a price-to-earnings ratio of 11.54 and a beta of 0.88. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24. The stock’s 50 day moving average price is $48.30 and its 200 day moving average price is $47.32.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. The firm’s revenue was down 2.3% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post $3.34 EPS for the current fiscal year.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.